前列腺癌
免疫系统
免疫疗法
医学
癌症研究
前列腺
癌症
免疫检查点
腺癌
CD8型
肿瘤科
免疫学
内科学
作者
Bhavneet Bhinder,Alison Ferguson,Michael Sigouros,Manik Uppal,Ahmed G. Elsaeed,Rohan Bareja,Hussein Alnajar,Kenneth Wha Eng,Vincenza Conteduca,Andrea Sboner,Juan Miguel Mosquera,Olivier Elemento,Himisha Beltran
标识
DOI:10.1158/1078-0432.ccr-22-3743
摘要
Patients with neuroendocrine prostate cancer (NEPC) are often managed with immunotherapy regimens extrapolated from small-cell lung cancer (SCLC). We sought to evaluate the tumor immune landscape of NEPC compared with other prostate cancer types and SCLC.In this retrospective study, a cohort of 170 patients with 230 RNA-sequencing and 104 matched whole-exome sequencing data were analyzed. Differences in immune and stromal constituents, frequency of genomic alterations, and associations with outcomes were evaluated.In our cohort, 36% of the prostate tumors were identified as CD8+ T-cell inflamed, whereas the remaining 64% were T-cell depleted. T-cell-inflamed tumors were enriched in anti-inflammatory M2 macrophages and exhausted T cells and associated with shorter overall survival relative to T-cell-depleted tumors (HR, 2.62; P < 0.05). Among all prostate cancer types in the cohort, NEPC was identified to be the most immune depleted, wherein only 9 out of the 36 total NEPC tumors were classified as T-cell inflamed. These inflamed NEPC cases were enriched in IFN gamma signaling and PD-1 signaling compared with other NEPC tumors. Comparison of NEPC with SCLC revealed that NEPC had poor immune content and less mutations compared with SCLC, but expression of checkpoint genes PD-L1 and CTLA-4 was comparable between NEPC and SCLC.NEPC is characterized by a relatively immune-depleted tumor immune microenvironment compared with other primary and metastatic prostate adenocarcinoma except in a minority of cases. These findings may inform development of immunotherapy strategies for patients with advanced prostate cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI